The biology and treatment of EML4-ALK non-small cell lung cancer

被引：486
作者：
Sasaki, Takaaki [1 ,2 ]
Rodig, Scott J. [3 ]
Chirieac, Lucian R. [3 ]
Janne, Pasi A. [1 ,2 ,4 ,5 ]
机构：
[1] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA 02115 USA
[2] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
[3] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA
[4] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA
[5] Harvard Univ, Sch Med, Boston, MA USA
来源：
EUROPEAN JOURNAL OF CANCER | 2010年 / 46卷 / 10期
基金：
美国国家卫生研究院;
关键词：
Non-small cell lung carcinoma; Translocation; Kinase inhibitor; Clinical trial; GROWTH-FACTOR-RECEPTOR; CLINICOPATHOLOGICAL FEATURES; FUSION GENE; ANAPLASTIC LYMPHOMA; TUMOR-SUPPRESSOR; MUTATIONS; ALK; KINASE; KRAS; ADENOCARCINOMA;
D O I：
10.1016/j.ejca.2010.04.002
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The fusion between echinoderm microtubule-associated protein-like 4 (EML4) and anaplastic lymphoma kinase (ALK),has recently been identified in a subset of non-small cell lung cancers (NSCLCs). EML4-ALK is most often detected in never smokers with lung cancer and has unique pathologic features. EML4-ALK is oncogenic both in vitro and in vivo and ALK kinase inhibitors are quite effective in pre-clinical model systems. More recently ALK inhibitors have entered clinical development and remarkably clinical efficacy has been observed in NSCLC patients harbouring EML4-ALK translocations. This review will focus on the biology, clinical characteristics, diagnosis and treatment of EML4-ALK NSCLC. (C) 2010 Elsevier Ltd. All rights reserved.
引用
收藏
页码：1773 / 1780
页数：8
相关论文
共 44 条
[1]  
Ahrendt SA, 2001, CANCER, V92, P1525, DOI 10.1002/1097-0142(20010915)92:6<1525::AID-CNCR1478>3.0.CO
[2]  
2-H
[3]   Epidermal growth factor receptor mutation in lung cancer are linked to bronchioloalveolar differentiation [J].
Blons, Helene ;
Cote, Jean-Francois ;
Le Corre, Delphine ;
Riquet, Marc ;
Fabre-Guilevin, Elisabeth ;
Laurent-Puig, Pierre ;
Danel, Claire .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2006, 30 (10) :1309-1315
[4]   Detection of t(2;5) in anaplastic large cell lymphoma - Comparison of immunohistochemical studies, FISH, and RT-PCR in paraffin-embedded tissue [J].
Cataldo, KA ;
Jalal, SM ;
Law, ME ;
Ansell, SM ;
Inwards, DJ ;
Fine, M ;
Arber, DA ;
Pulford, KA ;
Strickler, JG .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1999, 23 (11) :1386-1392
[5]   Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer [J].
Choi, Young Lim ;
Takeuchi, Kengo ;
Soda, Manabu ;
Inamura, Kentaro ;
Togashi, Yuki ;
Hatano, Satoko ;
Enomoto, Munehiro ;
Hamada, Toru ;
Haruta, Hidenori ;
Watanabe, Hideki ;
Kurashina, Kentaro ;
Hatanaka, Hisashi ;
Ueno, Toshihide ;
Takada, Shuji ;
Yamashita, Yoshihiro ;
Sugiyama, Yukihiko ;
Ishikawa, Yuichi ;
Mano, Hiroyuki .
CANCER RESEARCH, 2008, 68 (13) :4971-4976
[6]   Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma [J].
Christensen, James G. ;
Zou, Helen Y. ;
Arango, Maria E. ;
Li, Qiuhua ;
Lee, Joseph H. ;
McDonnell, Scott R. ;
Yamazaki, Shinji ;
Alton, Gordon R. ;
Mroczkowski, Barbara ;
Los, Gerrit .
MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) :3314-3322
[7]   Biomarkers of response to epidermal growth factor receptor inhibitors in non-small-cell lung cancer working group: Standardization for use in the clinical trial setting [J].
Eberhard, David A. ;
Giaccone, Giuseppe ;
Johnson, Bruce E. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (06) :983-994
[8]   EML4-ALK fusion transcript is not found in gastrointestinal and breast cancers [J].
Fukuyoshi, Y. ;
Inoue, H. ;
Kita, Y. ;
Utsunomiya, T. ;
Ishida, T. ;
Mori, M. .
BRITISH JOURNAL OF CANCER, 2008, 98 (09) :1536-1539
[9]  
Hernández L, 1999, BLOOD, V94, P3265
[10]   Female sex and bronchioloalveolar pathologic subtype predict EGFR mutations in non-small cell lung cancer [J].
Hsieh, RK ;
Lim, KH ;
Kuo, HT ;
Tzen, CY ;
Huang, MJ .
CHEST, 2005, 128 (01) :317-321
12345